Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Recruiting Phase 1 Interventional

RADIANT: Pre-op Radiation With Abemaciclib and Letrozole

ClinicalTrials.gov ID: NCT06139107

Public ClinicalTrials.gov record NCT06139107. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 3, 2026, 9:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

RADIANT Study: Pre-op Radiation With Abemaciclib Andletrozole in Early Stage Breast Cancer

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This phase 1b study investigates the safety and feasibility of combining pre-operative radiation therapy with Cyclin-Dependent Kinase 4 (CDK4/6) inhibitors in participants with hormone receptor positive/HER2 negative (HR+/HER2-) breast cancer. The study aims to assess the benefits of concurrent use of these treatments in a specific participant population, focusing on their safety and tolerability. The hypothesis is that the combination therapy will be well-tolerated, providing valuable insights into its effectiveness for future clinical applications.

Study identification

NCT ID
NCT06139107
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 1
Lead sponsor
Mridula George, MD
Other
Enrollment
15 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
60 Years and older
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 21, 2024
Primary completion
Sep 29, 2026
Completion
Sep 29, 2032
Last update posted
Nov 13, 2025

2024 – 2032

United States locations

U.S. sites
4
U.S. states
1
U.S. cities
4
Facility City State ZIP Site status
RWJBarnabas Health Clara Maas Medical Center Belleville New Jersey 07109 Recruiting
Cooperman Barnabas Medical Center Livingston New Jersey 07039 Recruiting
Rutgers Cancer Institute of New Jersey New Brunswick New Jersey 08903 Recruiting
RWJBarnabas Health - Robert Wood Johnson University Hospital Somerset Somerville New Jersey 08873 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06139107, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 13, 2025 · Synced Sep 3, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06139107 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →